UMIN試験ID | UMIN000038559 |
---|---|
受付番号 | R000043931 |
科学的試験名 | 膀胱癌におけるフレイルが治療選択に与える影響 (FRART-BC study) |
一般公開日(本登録希望日) | 2019/11/13 |
最終更新日 | 2022/12/06 09:11:10 |
日本語
膀胱癌におけるフレイルが治療選択に与える影響 (FRART-BC study)
英語
An observational study of the effect of frailty on treatment modality selection in patients with muscle-invasive bladder cancer: FRART-BC study
日本語
膀胱癌におけるフレイルが治療選択に与える影響 (FRART-BC study)
英語
An observational study of the effect of frailty on treatment modality selection in patients with muscle-invasive bladder cancer: FRART-BC study
日本語
膀胱癌におけるフレイルが治療選択に与える影響 (FRART-BC study)
英語
An observational study of the effect of frailty on treatment modality selection in patients with muscle-invasive bladder cancer: FRART-BC study
日本語
膀胱癌におけるフレイルが治療選択に与える影響 (FRART-BC study)
英語
An observational study of the effect of frailty on treatment modality selection in patients with muscle-invasive bladder cancer: FRART-BC study
日本/Japan |
日本語
膀胱癌
英語
Urinary bladder cancer
泌尿器科学/Urology |
悪性腫瘍/Malignancy
いいえ/NO
日本語
膀胱癌におけるフレイルが治療選択に与える影響を検討する
英語
To investigate the association between the frailty and treatment selection in patients with bladder cancer.
有効性/Efficacy
日本語
英語
探索的/Exploratory
該当せず/Not applicable
日本語
Primary purpose was the comparison of frailty between the patients who underwent radical cystectomy (RC group) and trimodal therapy for bladder preservation (TMT group).
英語
Primary purpose was the comparison of frailty between the patients who underwent radical cystectomy (RC group) and trimodal therapy for bladder preservation (TMT group).
日本語
Secondary purposes included the prevalence of frailty and the effect of frailty on treatment selection between the RC and TMT groups.
This study is a part of our prospective observational study (UMIN000025057). We planned to assess the intra-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) after the development of the CGA tool.
英語
Secondary purposes included the prevalence of frailty and the effect of frailty on treatment selection between the RC and TMT groups.
This study is a part of our prospective observational study (UMIN000025057). We planned to assess the intra-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) after the development of the CGA tool.
観察/Observational
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
20 | 歳/years-old | 以上/<= |
100 | 歳/years-old | 以下/>= |
男女両方/Male and Female
日本語
Patients with muscle invasive bladder cancer
Patients with frailty evaluation before surgery or trimodal therapy for bladder preservation
英語
Patients with muscle invasive bladder cancer
Patients with frailty evaluation before surgery or trimodal therapy for bladder preservation
日本語
Patients with bladder cancer who were not eligible for radical therapy such as radical cystectomy or trimodal therapy for bladder preservation
英語
Patients with bladder cancer who were not eligible for radical therapy such as radical cystectomy or trimodal therapy for bladder preservation
200
日本語
名 | 真吾 |
ミドルネーム | |
姓 | 畠山 |
英語
名 | Shingo |
ミドルネーム | |
姓 | Hatakeyama |
日本語
Hirosaki University School of Medicine
英語
Hirosaki University School of Medicine
日本語
Urology
英語
Urology
036-8562
日本語
5 Zaifu-chou, Hirosaki
英語
5 Zaifu-chou, Hirosaki
+81172395091
shingoh@hirosaki-u.ac.jp
日本語
名 | 真吾 |
ミドルネーム | |
姓 | 畠山 |
英語
名 | Shingo |
ミドルネーム | Yamamoto |
姓 | Hatakeyama |
日本語
Hirosaki University School of Medicine
英語
Hirosaki University School of Medicine
日本語
Urology
英語
Urology
036-8562
日本語
5 Zaifu-chou, Hirosaki
英語
5 Zaifu-chou, Hirosaki
+81172395091
shingoh@hirosaki-u.ac.jp
日本語
弘前大学
英語
Hirosaki University School of Medicine
日本語
日本語
Urology
日本語
英語
日本語
弘前大学
英語
Hirosaki University School of Medicine
日本語
日本語
Urology
日本の官庁/Japanese Governmental office
日本語
日本
英語
Japan
日本語
英語
日本語
英語
日本語
Hirosaki University School of Medicine
英語
Hirosaki University School of Medicine
日本語
5 Zaifu-chou
英語
5 Zaifu-chou
+81172395091
rinri@hirosaki-u.ac.jp
いいえ/NO
日本語
英語
日本語
英語
2019 | 年 | 11 | 月 | 13 | 日 |
https://pubmed.ncbi.nlm.nih.gov/33850749/
最終結果が公表されている/Published
https://pubmed.ncbi.nlm.nih.gov/33850749/
169
日本語
Frailty was significantly different between the RC and TMT in patients with MIBC and might be one of the key factors for treatment selection.
英語
Frailty was significantly different between the RC and TMT in patients with MIBC and might be one of the key factors for treatment selection.
2022 | 年 | 12 | 月 | 06 | 日 |
日本語
英語
日本語
英語
日本語
Frailty was evaluated in 169 patients with MIBC from January 2014 to September 2020 using the Fried phenotype, modified frailty index, and frailty discriminant score.
英語
Frailty was evaluated in 169 patients with MIBC from January 2014 to September 2020 using the Fried phenotype, modified frailty index, and frailty discriminant score.
日本語
none
英語
none
日本語
The primary purpose was comparing the frailty between the patients who underwent radical cystectomy (RC) with those who had trimodal therapy (TMT) for bladder preservation. Secondary purposes were comparing the frailty between the groups and the effect of TMT on overall survival adjusting the frailty by multivariate Cox proportional hazards analysis using inverse probability of treatment
英語
The primary purpose was comparing the frailty between the patients who underwent radical cystectomy (RC) with those who had trimodal therapy (TMT) for bladder preservation. Secondary purposes were comparing the frailty between the groups and the effect of TMT on overall survival adjusting the frailty by multivariate Cox proportional hazards analysis using inverse probability of treatment
日本語
英語
日本語
英語
試験終了/Completed
2017 | 年 | 01 | 月 | 06 | 日 |
2017 | 年 | 01 | 月 | 06 | 日 |
2017 | 年 | 01 | 月 | 06 | 日 |
2022 | 年 | 12 | 月 | 01 | 日 |
日本語
We evaluate frailty in patients with MIBC using modified Frailty index, Fried phenotype, and frailty discriminant score. Primary purpose was comparison of frailty between the patients who underwent radical cystectomy (RC group) and trimodal therapy for bladder preservation (TMT group). Secondary purposes were the prevalence of frailty between the groups and the effect of frailty on treatment selection. Exploratory purpose included overall survival (OS) comparison between the groups using the inverse probability of treatment weighting Cox regression model.This study is a part of our prospective observational study (UMIN000025057). We planned to assess the intra-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) when we successfully developed our CGA tool. In the UC cohort, we planned to evaluate 1) the intra-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) between the radical cystectomy and trimodal therapy in patients with MIBC (FRART-BC study), 3) between the neobladder and non-neobladder in patients with MIBC (FRAUD study), 4) in patients with upper tract urothelial carcinoma (FRAUT study), 5) metastatic urothelial carcinoma who underwent systemic chemotherapy and/or immunotherapy (FRAM-UC study), and 6) the association of baseline frailty and quality of life (FRAQ-UC study).
英語
We evaluate frailty in patients with MIBC using modified Frailty index, Fried phenotype, and frailty discriminant score. Primary purpose was comparison of frailty between the patients who underwent radical cystectomy (RC group) and trimodal therapy for bladder preservation (TMT group). Secondary purposes were the prevalence of frailty between the groups and the effect of frailty on treatment selection. Exploratory purpose included overall survival (OS) comparison between the groups using the inverse probability of treatment weighting Cox regression model.This study is a part of our prospective observational study (UMIN000025057). We planned to assess the intra-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) when we successfully developed our CGA tool. In the UC cohort, we planned to evaluate 1) the intra-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) between the radical cystectomy and trimodal therapy in patients with MIBC (FRART-BC study), 3) between the neobladder and non-neobladder in patients with MIBC (FRAUD study), 4) in patients with upper tract urothelial carcinoma (FRAUT study), 5) metastatic urothelial carcinoma who underwent systemic chemotherapy and/or immunotherapy (FRAM-UC study), and 6) the association of baseline frailty and quality of life (FRAQ-UC study).
2019 | 年 | 11 | 月 | 12 | 日 |
2022 | 年 | 12 | 月 | 06 | 日 |
日本語
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000043931
英語
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043931
研究計画書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ仕様書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ | |
---|---|
登録日時 | ファイル名 |